Standard Methotrexate Dosing Guidelines
Methotrexate dosing varies by condition—typically 7.5–25 mg weekly orally for rheumatoid arthritis (RA), higher for cancer (e.g., 1–5 g/m² IV). Body surface area (BSA) or weight-based calculations apply in oncology, while fixed weekly doses suffice for autoimmune uses. Renal function, assessed via creatinine clearance (CrCl), drives adjustments more than age alone.[1]
Why Age Affects Dosing: Renal Clearance and Pharmacokinetics
Older adults (over 65) experience reduced glomerular filtration rate (GFR), even with normal serum creatinine, leading to 20–50% lower methotrexate clearance. This raises toxicity risk from prolonged exposure. Half-life extends from ~7–10 hours in young adults to 12–15+ hours in the elderly. Guidelines recommend baseline GFR screening and dose cuts if CrCl <60 mL/min.[2][3]
Recommended Adjustments by Age Group
- Adults under 65: Full dose if CrCl >60 mL/min; reduce 25–50% if 30–60 mL/min; avoid if <30 mL/min.
- 65–75 years: Start 25–50% lower (e.g., 7.5–10 mg/week for RA), monitor closely; increase only if tolerated.
- Over 75: Often cap at 50–75% of standard (e.g., ≤10 mg/week for RA), with frequent CrCl checks. In cancer, BSA-normalized doses drop further if GFR <50% predicted for age.[4]
| Age Group | Typical RA Dose Adjustment | Cancer Dose Adjustment Example |
|-----------|----------------------------|-------------------------------|
| <65 | 7.5–25 mg/week | Full BSA-based (e.g., 3 g/m²) |
| 65–75 | 7.5–15 mg/week | Reduce 25% if CrCl <60 |
| >75 | ≤10 mg/week | Reduce 50%+; consider alternatives |
Monitoring and Risks in Older Patients
Check CBC, liver enzymes, and CrCl every 1–3 months; more often if dose >15 mg/week. Elderly face higher myelosuppression (30% incidence vs. 10–15% in young), stomatitis, and infections due to frailty and polypharmacy. Folate supplementation (1 mg/day) mitigates some risks.[5]
How This Compares to Other DMARDs for Elderly RA
Unlike leflunomide (no age-specific cuts), methotrexate requires stricter renal tweaks. Sulfasalazine or hydroxychloroquine often preferred first-line in frail elderly for better safety profiles.[6]
[1]: UpToDate: Methotrexate Dosing in Rheumatic Diseases
[2]: American College of Rheumatology Guidelines 2021
[3]: FDA Label: Methotrexate
[4]: British National Formulary (BNF)
[5]: Journal of Rheumatology: Age-Related Toxicity (2018)
[6]: EULAR Recommendations for RA Management